What This MannKind Filing Reveals About Three Years of Underperformance
Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million.
Overview
Sanjay R. Singh, EVP Technical Operations at MannKind Corporation (NASDAQ:MNKD), disposed of 46,795 shares of common stock on July 15, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($4.09); post-transaction value based on July 15, 2026 market close ($4.09).
Details
MannKind Corporation is a biopharmaceutical firm with a market capitalization of $1.2 billion focused on developing and commercializing respiratory-delivered treatments. The company has achieved TTM revenue of $360.8 million while managing a net loss of $23.9 million, reflecting the capital-intensive nature of biopharmaceutical development and commercialization. MannKind's competitive positioning centers on its proprietary inhalation technology platform and specialized focus on respiratory-delivered therapeutics for endocrine and pulmonary conditions.
Source
Originally published at www.fool.com.